How does 0NKY's PS Ratio compare to its peers?

0NKY is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (2.1x).

How does 0NKY's PS Ratio compare vs other companies in the European Healthcare Industry?

0NKY is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Healthcare industry average (0.6x).

What is 0NKY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0NKY's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of 0NKY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 0NKY's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Arzneiwerk VIDA LSE:0NKY Stock Report

Last Price

€0.51

Market Cap

€3.0m

7D

-2.1%

1Y

n/a

Updated

01 Feb, 2025

Data

Company Financials

Arzneiwerk AG VIDA

LSE:0NKY Stock Report

Market Cap: €3.0m

0NKY Stock Overview

Engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. More details

0NKY fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Negative shareholders equity

Earnings have declined by 60.1% per year over past 5 years

Has less than 1 year of cash runway

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Arzneiwerk AG VIDA Competitors

PHSC

AIM:PHSC

UK£2.0m

GENinCode

AIM:GENI

UK£7.3m

IQ-AI

LSE:IQAI

UK£3.5m

Surgical Innovations Group

AIM:SUN

UK£4.9m

Price History & Performance

Summary of share price highs, lows and changes for Arzneiwerk VIDA
Historical stock prices
Current Share Price	€0.51
52 Week High	€0.74
52 Week Low	€0.51
Beta	0.73
1 Month Change	-19.20%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-94.13%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	0NKY	GB Healthcare	GB Market
7D	-2.1%	0.9%	2.0%
1Y	n/a	-20.5%	10.8%

Return vs Industry: Insufficient data to determine how 0NKY performed against the UK Healthcare industry.

Return vs Market: Insufficient data to determine how 0NKY performed against the UK Market.

Price Volatility

Is 0NKY's price volatile compared to industry and market?
0NKY volatility
0NKY Average Weekly Movement	n/a
Healthcare Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.8%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0NKY's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0NKY's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	39	Sascha Knoche	www.arzneiwerk.ag

Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorporated in 1996 and is based in Berlin, Germany.

Arzneiwerk AG VIDA Fundamentals Summary

How do Arzneiwerk VIDA's earnings and revenue compare to its market cap?
0NKY fundamental statistics
Market cap	€3.02m
Earnings (TTM)	-€2.15m
Revenue (TTM)	€59.68m

0.1x

P/S Ratio

-1.4x

P/E Ratio

Is 0NKY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0NKY income statement (TTM)
Revenue	€59.68m
Cost of Revenue	€56.10m
Gross Profit	€3.58m
Other Expenses	€5.73m
Earnings	-€2.15m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.34
Gross Margin	6.00%
Net Profit Margin	-3.60%
Debt/Equity Ratio	-201.1%

How did 0NKY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/01 12:36
End of Day Share Price	2025/01/29 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arzneiwerk AG VIDA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Marcus Pratsch	Dz Bank Ag